JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Strona główna・Stock List・Lantheus Holdings Inc

Lantheus Holdings Inc

Closed

SectorHealthcare

84.22 1.78

Buy Sell

Overview

Share price change

24h

Current

Min

83.55

Max

84.3

Key metrics
By Trading Economics
Income	26M 54M
Sales	23M 407M
P/E Sector Avg	24.625 60.328
Profit margin	13.296
Employees	1,193
EBITDA	31M 98M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+12.18% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	475M 5.5B
Previous open	82.44
Previous close	84.22

News Sentiment

By Acuity

50%

141 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

79.24 / 103.64 Support & Resistance

Lantheus Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Major Central Bank -2-

24 kwi 2026, 19:19 UTC

Acquisitions, Mergers, Takeovers

Intertek Group Rejects EQT's Revised Offer

26 kwi 2026, 23:48 UTC

Market Talk

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26 kwi 2026, 23:44 UTC

Earnings

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26 kwi 2026, 23:44 UTC

Earnings

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26 kwi 2026, 23:36 UTC

Market Talk

Major News Events

Gold Falls Amid Dollar's Strength -- Market Talk

26 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24 kwi 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Scoring the Cook Era -- Barrons.com

24 kwi 2026, 20:51 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

24 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 kwi 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 20:09 UTC

Earnings

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 kwi 2026, 19:48 UTC

Market Talk

Major News Events

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 kwi 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 kwi 2026, 19:22 UTC

Earnings

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 kwi 2026, 19:06 UTC

Earnings

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 kwi 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 kwi 2026, 18:30 UTC

Acquisitions, Mergers, Takeovers

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 kwi 2026, 18:28 UTC

Acquisitions, Mergers, Takeovers

Intertek Rejects Revised EQT Offer

24 kwi 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 kwi 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 kwi 2026, 17:42 UTC

Earnings

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 kwi 2026, 17:28 UTC

Earnings

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Peer Comparison

Price change

Lantheus Holdings Inc Forecast

Price Target

By TipRanks

12.18% upside

12 Months Forecast

Average 94.6 USD 12.18%

High 110 USD

Low 85 USD

Based on 7 Wall Street analysts offering 12 month price targets forLantheus Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Lantheus Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

79.24 / 103.64Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

141 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.